RPL7P20

Across TCGA pan-cancer cohorts, RPL7P20 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL7P20’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RPL7P20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL7P20 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

COAD, BRCA, and READ are the cancer types where RPL7P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	II,III,IV	+0.197	<.001	6	view →
BRCA	Female	All	−0.037	.015	4	view →
READ	All	III,IV	+0.385	.013	3	view →
LUAD	Male	All	+0.101	.040	2	view →
LIHC	Female	All	+0.046	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL7P20–COAD

Open the COAD breakdown →